entertainment function. The three domains were moderately correlated with each other (PCCϭ0.5 to 0.6, pϽ0.001). Muscle strength was weakly related with limitations in gross motor function (PCCϭ-0.20, PϽ0.001), and social and entertainment function (PCCϭ-0.13, PϽ0.001); but not significantly related with limitation in fine motor function (PCCϭ-0.06, pϭ0.09). CONCLUSIONS: These findings suggest that in a sample of US elderly aged 60-80 years the NHANES physical function limitation questionnaire has three domains, of which the gross motor function domain and social and entertainment function domain are weakly related with muscle strength.
OBJECTIVES: Patient Reported Outcomes (PROs) play an important role in evaluating patient quality of life and comparative efficacy of various treatments. Another potential use of PROs is for chronic disease management, which can provide useful data to physicians and patients. We developed a novel web and phone based PROs tool for management of prostate cancer disease. METHODS: PRO methods for prostate cancer were reviewed by analyzing published clinical studies. KOLs and patient advocacy groups were interviewed to obtain their input for design of PRO disease management tool. Recent technologies for developing such tools were reviewed by analyzing available electronic PRO tools. PROCDIM design was developed based on secondary research and primary interviews. RESULTS: PROCDIM was designed to capture patient reported outcomes data such as Quality of Life (using five attributes), adverse events (six commonly reported AEs), medications and OTC drugs history, PSA antigen score, past surgery and radiation therapy and record of physician appointments. Patients could enter data into PROCDIM using web or phone (iphone or andriod) based systems. Data from PROCDIM could be emailed by patient to provider or could be downloaded by tethering phone to computer. Pilot data was captured by testing PROCDIM with physicians and patient advocacy groups. Based on interviews, PROCDIM was rated superior and highly user friendly compared to current chronic disease management tools. Patient outcomes data would be collected from a planned IRB approved study. CONCLUSIONS: PROCDIM is a valuable tool to capture several patients reported outcomes and data for chronic disease management. Such tools could be used for collecting data for disease management, clinical trial and for observational studies for various chronic diseases. 
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ASSESSMENT OF PRO LABELS CLAIMS GRANTED BY THE FDA AS COMPARED TO THE EMA
OBJECTIVES:
In 2009, the United States (US) Food and Drug Administration (FDA) issued a formal guidance for the use of patient-reported outcomes (PRO) in support of labeling claims, whereas the European Medicines Agency (EMA) offers insight in a 2007 reflection paper in lieu of formal guidance. To evaluate and describe decision making by the FDA and EMA, a review of PRO label claims granted for new molec-ular entities and biologic license applications from 2006 through 2010 was conducted. The purpose of this research was to evaluate consistencies and discrepancies and to highlight trends in the acceptance of PRO claims across agencies. METHODS: A listing was created of drug approvals granted by both the FDA and the EMA. PRO claims were compared using US Drug Approval Packages and European Public Assessment Reports packages to determine any instances where claims made for the same product by the same company were similar or different. RESULTS: A total of 75 products were identified as having been approved by both agencies. Of these, a total of 35 (40%) were granted at least one PRO claim by the EMA, as compared with 14 (19%) by the FDA. Most claims in the US focused on signs and symptoms; however, claims in the European Union were more likely to include higher-order concepts such as health-related quality of life (HRQL) and functioning (29% EMA, 9% FDA). Only a small number of products (ϳ10%) had the same claims granted by both agencies. CONCLUSIONS: The EMA is more likely than the FDA to grant PRO claims and to grant claims for higher-order constructs such as HRQL and functioning. Additionally, there appears to be poor concordance between claims granted by both agencies, which may demonstrate a need for sponsors to develop agency-specific PRO strategies. (Gnanasakthy, 2012) has shown that about 24% of New Drug Applications (NDAs) and Biologic License Applications (BLAs) approved by the Food and Drug Administration (FDA) between 2006 and 2010 had at least one patient-reported outcome (PRO) label claim, and most claims (74%) were granted for PRO endpoints that were also primary endpoints. Claims based on primary endpoints are likely to be fully promoted by the manufacturers; however, the extent to which manufacturers promote claims based on secondary PRO endpoints is unknown. The purpose of this review is to assess the extent of promotion of PRO label claims for six products with nonprimary PRO endpoints. METHODS: All six pharmaceutical products that received PRO label claims based on nonprimary PRO endpoints between 2006 and 2008 were reviewed. Promotional documents distributed in the US by the manufacturers of these drugs between the year of launch and 2011 were identified from a PharmaVoxx database. To assess the intensity of promotional activity, circulation of these documents was calculated based on quarterly distributions. Two researchers reviewed the documents using standard criteria. Promotional activities based on nonprimary PRO endpoints claims were compared with total number of messages. Disease-awareness and management documents and all videos, CDs, and DVD were excluded. RESULTS: Manufacturers of the six products distributed a total of 973 unique promotional documents 2998 times. Messages based on primary endpoints were distributed 1,798 times, whereas messages relating to secondary PRO endpoints were distributed 1200 times (40% of distributions), and varied between products (4% to 70%). Messages relating to PROs were targeted mostly at patients and consumers (65%) and physicians and health care professionals (34%). CONCLUSIONS: Promotion of PRO messages based on nonprimary endpoints is much lower than those based on primary endpoints, indicating that manufacturers do not always optimize the potential of PRO messages.
PIH54
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USE OF PRO ANALYSIS IN HEALTH TECHNOLOGY ASSESSMENTS
Rubinstein E, Jaksa A, Ho YS, Daniel K Context Matters Inc, New York, NY, USA OBJECTIVES: ISPOR has focused on patient reported outcomes (PROs) since the second annual European Congress in 1998, but the prevalence of PROs in product evaluation for Health Technology Assessments (HTAs) is not well studied. This study examines the prevalence of PROs for reviews published by nine agencies in 2005-2011: PBAC, CADTH, HAS, IQWiG, SMC, NHS Scotland, NICE, DERP, AHRQ. METHODS: Analysis of all HTA reports from 2005-2011 in the aforementioned agencies for 13 disease areas: Alzheimer's Disease, Anemia in Cancer and Chronic Kidney Disease, Chronic Myelogenous Leukemia, Clostridium Difficile, Depression, Diabetes, Glaucoma, Hepatitis C (adults and pediatrics), HIV (adults and pediatrics), HPV, Osteoporosis, Ovarian Cancer, Parkinson's Disease. RESULTS: Among the 324 total reviews from 2005-2011, 91 (28%) reviews report PROs. The use of PROs increased steadily, from 11.1% in 2005 to 42.5% in 2011. We find wide variation across disease conditions and agencies in the use of PROs. For several disease conditions there is no use of PROs, but Anemia in Cancer, Ovarian Cancer and Parkinson's Disease reviews use PROs at least 75% of the time. Use by agencies varies from 9.8% (HAS) to 66.7% (IQWiG; NHS Scotland). Reviews of disease conditions are distributed unequally across agencies and vice versa. This raises the possibility that agencies' differing use of PROs might simply reflect differences across disease conditions in PRO use, or the reverse. We find evidence that agencies tend to behave differently depending on the disease condition under review. A significant part of the variation across agencies arises from their emphasis on different disease conditions. CONCLUSIONS: HTAs use PROs as an evaluator less than a third of the time. The use of PROs is steadily increasing over time. Therapeutic area drives the use of PROs.
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